Search

Your search keyword '"Ji, Dexiang"' showing total 17 results
Start Over Author "Ji, Dexiang" Search Limiters Full Text
17 results on '"Ji, Dexiang"'

5. Safety, Pharmacokinetics and Preliminary Efficacy of HMPL-523 in Adult Patients with Primary Immune Thrombocytopenia: A Randomized, Double-Blind and Placebo-Controlled Phase 1b Study

Author

Yang, Renchi, primary, Zhou, Hu, additional, Hu, Yu, additional, Yin, Jie, additional, Li, Junmin, additional, Chen, Wenming, additional, Huang, Ruibin, additional, Gong, Yuping, additional, Luo, Chenwei, additional, Xiaofan, Liu, additional, Mei, Heng, additional, Ding, Bingjie, additional, Gu, Chengyuan, additional, Sun, Huiping, additional, Yun, Leng, additional, Ji, Dexiang, additional, Li, Yan, additional, Shi, Haiyan, additional, Yin, Hongyan, additional, Fan, Songhua, additional, Wang, Jian, additional, and Su, Weiguo, additional

Published
2021
Full Text
View/download PDF

6. Acute B Lymphoblastic Leukemia Developing in Patients with Multiple Myeloma: Presentation of Two Cases

Author

Li Na, Li Fei, Ji Dexiang, Zhang Zhanglin, and Jiang Mei

Subjects
Male, Oncology, medicine.medical_specialty, lcsh:Internal medicine, acute lymphoblastic leukemia, Immunophenotyping, immunophenotyping, Internal medicine, Humans, Medicine, In patient, genetics, Letters to the Editor, lcsh:RC31-1245, Multiple myeloma, Aged, Therapy related, business.industry, B lymphoblastic leukemia, lcsh:RC633-647.5, therapy-related, Hematology, lcsh:Diseases of the blood and blood-forming organs, Precursor Cell Lymphoblastic Leukemia-Lymphoma, medicine.disease, multiple myeloma, Female, Presentation (obstetrics), business
Published
2019

15. CyclinG1 Amplification Enhances Aurora Kinase Inhibitor-Induced Polyploid Resistance and Inhibition of Bcl-2 Pathway Reverses the Resistance

Author

Zhang, Wenfeng, primary, Xu, Jie, additional, Ji, Dexiang, additional, Li, Zhangyun, additional, He, Wenxing, additional, Yang, Fei, additional, Lan, Huiyin, additional, Wang, Yu, additional, Wu, Zhengping, additional, Liu, Xiaoshan, additional, Huang, Shanhua, additional, Li, Longkun, additional, and Zhou, Weihua, additional

Published
2017
Full Text
View/download PDF

17. Porcine Anti-Lymphocyte Globulin, Cyclosporine A Plus Thrombopoietin Receptor Agonists Achieved Similar Efficacy and Survival Compared to Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Aplastic Anemia.

Author

Zhao R, Ji D, Zhou Y, Qi L, and Li F

Abstract

Background: Immunosuppressive therapy (IST) with horse or rabbit anti-human thymocyte immunoglobulin (h-/r-ATG) and hematopoietic stem cell transplantation (HSCT) are two baseline treatments for severe aplastic anemia (SAA) and transfusion-dependent non-severe aplastic anemia (TD-NSAA) patients. Addition of thrombopoietin receptor agonists (TPO-RAs) to standard IST therapy (h-/r-ATG) has greatly improved the survival of SAA, whereas porcine anti-lymphocyte globulin (p-ALG) combined with TPO-RAs still had a matter of debate., Methods: We retrospectively compared the data of 48 AA patients in our center between 2020 and 2022, 23 AA patients received with p-ALG ± TPO-RAs, 25 AA patients underwent matched sibling donor (MSD-) or haploidentical (haplo-) HSCT., Results: For patients in the HSCT group, the ORR was 90.9% which was significantly higher than that in the IST±TPO-RAs group (45.5%, P = 0.001) at 3 months; moreover, patients who underwent HSCT achieved faster transfusion independence, better CR rate, shorter time of recovery normal blood routine, and the percentage of normal blood routine (all P < 0.05) compared with IST±TPO-RAs group. However, the ORR were similary at 6 months in the two groups (95.5% vs 81.8% P = 0.342), with a median follow up of 19.8 months (range, 0.3-38.2 months), the 2-year FFS and OS in the two cohorts has no different. Subgroup analysis further indicated that the 2-year FFS and OS were similar between IST+TPO-RAs and haplo-HSCT subgroups, as well as in IST+TPO-RAs and MSD-HSCT cohorts. Moreover, the first-time hospitalizations were much more expensive in the HSCT group than in the IST±TPO-RAs group (402 756 vs. 292 902 yuan, P = 0.002)., Conclusion: P-ALG-based-IST±TPO-RAs is a good treatment option with similar FFS and OS compared to allo- HSCT for AA patients without the opportunity of HSCT., Competing Interests: The authors declare no competing interests in this work., (© 2024 Zhao et al.)

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results